Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 22, 2001

View Archived Issues

MGI Pharma reviews progress during 2000

Ilex Oncology updates year-end 2000 developments; highlights plans for 2001

Year-end 2000 at The Medicines Company marked by FDA approval of Angiomax

FDA advisory committee recommends changes in Vioxx and Celebrex labeling

Preclinical data support clinical development of BN-80915, a lead homocamptothecin

FeRx initiates phase I/II trial of MTC-DOX for metastatic liver cancer

Hollow fiber model used to study in vitro cytotoxic activity of CHS-828

Cognetix awarded Phase I SBIR grant to study potential asthma treatment

Medarex and Immusol to develop fully human antibody therapeutics

BioNumerik partners with Asta Medica for oncology drug development

Effects of orally active SGLT inhibitor in animal model of type 2 diabetes

Therion Biologics and the NCI move CEA-TRICOM cancer vaccine to phase I

AltaRex initiates collaboration with University of Alberta researcher for hepatitis B treatment

New research program for CRL-5861 in cancer

Rasagiline may be preferable to selegiline for treatment of Parkinson's disease

Panacea enters collaborative agreement with MIT for anticancer antibodies

Milestone payment received by AxyS from Merck under osteoporosis research collaboration

Therapeutic agents for drug addiction, withdrawal, etc., claimed by Knoll

Vical broadens clinical development of Allovectin-7

Improved nucleoside immunomodulators in the ICN pipeline

Noval anticlotting agents reported in recent patent by Novo Nordisk

Cell Pathways presents series of apoptosis-inducing antineoplastic agents

BioTransplant-Novartis joint venture begins operations in the area of xenotransplantation

Phase III trial of MT-100 successfully concluded

BMS synthesizes and tests new heterocyclic aminopyrrolidine melatonergic agents

Spanish research institute discovers new bafilomycins in marine microbe

Preparation and use of potassium channel blockers described by NeuroSearch

Recent patent covers antiinflammatory agents from Ajinomoto

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...